{'fraction_non_alphanumeric': 0.027129337539432176, 'fraction_numerical': 0.010725552050473186, 'mean_word_length': 5.030418250950571, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Effects of low-dose recombinant interleukin-2 in human malignancies.

PURPOSE
This article reviews the literature regarding the immunomodulatory activity and clinical efficacy of low-dose recombinant interleukin-2 (rIL-2) therapy. The aim of future rIL-2 biotherapies for the treatment of cancer is to standardize the lowest dosage of rIL-2 required to activate the in vivo anticancer immune response without harmful toxicity.


PATIENTS AND METHODS
Patients with various solid tumor malignancies have been treated with either subcutaneous or intravenous low-dose rIL-2 at doses ranging from < 1 MIU/m2/day to 6 MIU/day. In these studies the immunomodulatory effects of low-dose rIL-2 administration have been evaluated by measuring cytokine production and immune cell numbers and activity.


RESULTS
Prolonged and continuous injections of low-dose rIL-2 primarily increase activated T lymphocyte number, whereas intermittent and sequential injections of low-dose rIL-2 seem to induce a preferential increase in activated natural killer cells and eosinophils. Moreover, natural killer cells and eosinophil number increase progressively during the treatment, whereas T cells do not increase further after 2 weeks of treatment with low-dose rIL-2. The effect of low-dose rIL-2 is influenced by pretreatment systemic inflammation as well as neuroendocrine factors, such as pineal gland function.


CONCLUSION
Low-dose rIL-2 is not only less toxic than high-dose rIL-2 therapy, but is also the most physiologic immunotherapeutic strategy to activate the anticancer immune response in vivo.